Navigation Links
Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
Date:12/7/2011

f siRNA molecules selectively to liver cells including hepatocytes. Additionally, the Company has a platform of novel siRNA molecules based around its AtuRNAi chemical modification technology, which provides a number of advantages over conventional siRNA molecules. Silence's unique RNAi assets also include structural features for RNAi molecules and specific design rules for increased potency and reduced off-target effects of siRNA sequences.

The Company's lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutic candidates in the area of oncology. Atu027 incorporates two of the Company's technologies, AtuRNAi and AtuPLEX. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as repeated, intravenous administration. Encouraging interim safety and pharmacokinetic data were presented at the American Society of Clinical Oncology Annual Meeting in June 2011. The study is expected to be completed in the first half of 2012.

The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including Dainippon Sumitomo, Pfizer/Quark, and Novartis/Quark. Silence is actively pursuing the establishment of additional partnerships. Silence Therapeutics has operations in both Berlin and London.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Provides Corporate and Development Update
2. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
3. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
4. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
5. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
6. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
7. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
8. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
9. Silence Therapeutics Appoints New Vice President of Research
10. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
11. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 Space is ... exploration of space requires astronauts to maintain consistently high ... success, and prevent potential errors and accidents. Despite the ... known about how cognition is affected by prolonged spaceflight, ... Now, Penn Medicine researchers are poised to help ...
(Date:11/26/2014)... The ETC (Emerging Technology Centers) ... announced today that applications for AccelerateBaltimore™ (AB) 2015 ... you have a big idea?,” asked ETC’s President ... about it. AccelerateBaltimore helps you and your big ... 13 weeks.” Interested game changers with “big ...
(Date:11/26/2014)... November 25, 2014 SonaCare Medical, ... Ultrasound (HIFU) devices, recently participated in the American ... Mass 360° .” Key opinion leaders in urology ... related to small renal masses while attendees had ... ablative technologies in hands-on labs. Attendees at the ...
(Date:11/26/2014)... November 25, 2014 The Pittcon marketing ... official conference and exposition mobile app, ... download in the App Store for iOS and Android ... resource tool before, during and after the event. It ... on exhibiting companies, technical sessions, Conferee Networking sessions and ...
Breaking Biology Technology:Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Pittcon Releases 2015 Mobile App 2
... Ventures, a venture capital,firm specializing in life science ... firm as its fourth partner. Broderick brings more,than ... fund,management, and technology commercialization. Before coming to ... in Milwaukee, WI, where he served on its ...
... EDT, EDMONTON, BELLEVUE, WASHINGTON, Sept. 12 /PRNewswire-FirstCall/ ... (the "Company") today announced that,the Company,s Board of ... of incorporation from the federal jurisdiction of Canada ... of America through a plan of,arrangement. Under the ...
... Inc., a,biotechnology company translating the complexity of human ... its president and,CEO, Dr. Keith O. Elliston, has ... Summit in Arlington, Va., September 17-18. Dr. ... on,"Enhancing Development and Commercial Value Added in Care ...
Cached Biology Technology:Dan Broderick Joins Prolog Ventures as Partner 2Dan Broderick Joins Prolog Ventures as Partner 3Biomira Announces Plan to Reincorporate in the United States 2Biomira Announces Plan to Reincorporate in the United States 3Biomira Announces Plan to Reincorporate in the United States 4Biomira Announces Plan to Reincorporate in the United States 5Biomira Announces Plan to Reincorporate in the United States 6Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit 2
(Date:11/4/2014)... , November 4, 2014   ... market growth   Fuel3D , a developer ... a funding round totaling $6.4 million (£4 million). This funding ... secured earlier this year and paves the way for the ... The funding round was led by Chimera Partners ...
(Date:11/3/2014)... study published in this month,s Proceedings of ... of a recently discovered communication molecule of the body,s ... known to limit inflammation and the current study reports ... the ability of the immune system to recognize and ... IL-37,s effect on the immune system now allows us ...
(Date:11/2/2014)... NEW ORLEANS, LA (2 November 2014)—In support of a ... the Bill & Melinda Gates Foundation today announced an ... PATH Malaria Vaccine Initiative (MVI) in building new vaccines ... and help realize the "accelerating to zero" agenda. Such ... providing what could be called an "immunological bed net." ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3PNAS: From HIV to cancer, IL-37 regulates immune system 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4
... LOUIS - Researchers at the Saint Louis University School ... causes Parkinsons disease a breakthrough finding that could ... to treat one of the most common and debilitating ... Parkinsons disease, which afflicts more than 1.5 million Americans, ...
... Institute will host its third annual Ocean Future Symposium, ... 12 p.m., in the Woodrow Wilson auditorium. The symposium, ... Communities for Action," will envision a future where media ... to increase the general publics coastal and ocean literacy. ...
... of amphibians have been discovered in 330 million-year-old rocks ... and bodies of three previously unknown, foot-long salamander-like critters ... "Body impressions like this are wholly ... the New Mexico Museum of Natural History and Science. ...
Cached Biology News:St. Louis University scientists identify chemical that triggers Parkinson's disease 2Abel to receive posthumous Ocean and Coastal Leadership award 2Ancient amphibians left full-body imprints 2
GLP-compliant, CLIA-certified DNA sequencing service. ASQ and SQA certified quality assurance staff. Auditors welcome....
Sequencing and primer design rolled into one. Just give us your clone and a reference sequence, and we'll do the rest. Single-strand or double-strand coverage. Guaranteed results....
... to human XAB2 (amino terminus) XAB2 ... its interaction with XPA. Immunoprecipitation experiments have ... interacts with the transcription-coupled repair-specific proteins CSA ... polymerase II. Microinjection experiments with XAB2 antibodies ...
... using advanced automated high throughput microplate processing equipment that dispenses ... accommodate virtually any lot size of the following formats (with ... 8 and 12 well strips, ... 384 well microplate, 1536 ...
Biology Products: